2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

4:30PM-6:00PM: Abstract Number: 2100

Hypomethylation in Enhancer and Promoter Regions of Interferon Regulated Genes in Multiple Tissues Is Associated with Primary Sjögren’s Syndrome

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2094

Identification of Gout Flare Using an Administrative Claims Based Algorithm

Epidemiology and Public Health III: Risk Factors, Treatment and Outcomes of Gout and OA

4:30PM-6:00PM: Abstract Number: 2136

Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis II

4:30PM-6:00PM: Abstract Number: 2110

Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout

Metabolic and Crystal Arthropathies I: Therapeutics

4:30PM-6:00PM: Abstract Number: 2088

Immature Dendritic Are Potent OC Precursors in RA and Are Targeted By RA-Specific Antibodies

Biology and Pathology of Bone and Joint: Bone Remodeling

4:30PM-6:00PM: Abstract Number: 2096

Immune Dysregulation in Patients with TRNT1 Deficiency

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2173

Impact of Smoking on Patient-Reported Disease Status and Symptoms Among Women with Lupus

ARHP III: Epidemiology and Public Health

4:30PM-6:00PM: Abstract Number: 2123

Incidence and Prognosis of Neonatal and Late-Onset Dilated Cardiomyopathy Associated with Cardiac Neonatal Lupus

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects

4:30PM-6:00PM: Abstract Number: 2091

Influence of Increasing Physical Activity on Longitudinal Changes in Disability Status Among Inactive Older Adults

Epidemiology and Public Health III: Risk Factors, Treatment and Outcomes of Gout and OA

4:30PM-6:00PM: Abstract Number: 2104

Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks

Health Services Research II: Rheumatoid Arthritis Treatment and Healthcare Utilization

4:30PM-6:00PM: Abstract Number: 2154

Inhibition of Gli Ameliorates the Pro-Fibrotic Effects of Transforming Growth Factor-Î² in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2086

Inhibition of Macrophage Inflammatory Protein 1-Alpha (CCL3) Significantly Reduced Bone Resorption in Vitro and the Development of Erosive Joint Pathology in Collagen-Induced Arthritis

Biology and Pathology of Bone and Joint: Bone Remodeling

4:30PM-6:00PM: Abstract Number: 2151

Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2155

Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2107

Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.

Health Services Research II: Rheumatoid Arthritis Treatment and Healthcare Utilization

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].